FindMyKOL

Susan Bates, MD

Enriched profile

Professor of Medicine at CUMC; Director, Translational Cancer Medicine · NewYork-Presbyterian

ORCIDNone on fileNPI↗
✓ Itemized profile
Region🇺🇸 New York, NY · Northeast · United StatesSpecialtyMedical OncologyFocusBreast Cancer+7
Active KOLFindMyKOL type: RegionalLatest publicationNone indexedOnline presenceNone verifiedPayments2022–2025NIH fundingNone on fileWhy? →

Susan Bates is Professor of Medicine at CUMC; Director, Translational Cancer Medicine at NewYork-Presbyterian. ClinicalTrials.gov lists 14 registered studies with this person as an investigator.

Data verified 27 Oct 2026

Overview

Updated 28 Oct 2026

Susan E. Bates, M.D., is Professor of Medicine at CUMC at NewYork-Presbyterian / Columbia University Irving Medical Center. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 4 companies.

  • Top research focus: Breast Cancer
  • 14 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 4 companies

Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Lung Cancer (NSCLC/SCLC)6 trialsBreast Cancer3 trialsCarcinoma, Small Cell3 trialsNeoplasm Metastasis2 trialsLymphoma1 trialOvarian / Gynecologic Cancer1 trialUterine Cervical Neoplasms1 trialKidney Neoplasms1 trialBrain Neoplasms1 trialSmall Cell Lung Carcinoma1 trial

Research focus

OpenAlex concept fingerprint
Breast CancerLung Cancer (NSCLC/SCLC)Brain NeoplasmsKidney NeoplasmsLymphomaNeoplasm MetastasisOvarian / Gynecologic CancerUterine Cervical Neoplasms

Drugs & molecules

across trials, industry payments and publications
Onivydegeneric · IrinotecanClinical trials—Industry payments3Publications—CapmatinibClinical trials1Industry payments—Publications—LanreotideClinical trials—Industry payments1Publications—OsimertinibClinical trials1Industry payments—Publications—Pemazyregeneric · PemigatinibClinical trials—Industry payments1Publications—RamucirumabClinical trials1Industry payments—Publications—Screening PlatformClinical trials1Industry payments—Publications—Tevimbrageneric · TislelizumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
National Cancer Institute (NCI)Clinical trials6Industry payments—Daiichi Sankyo Inc.Clinical trials—Industry payments3Ipsen Biopharmaceuticals, IncClinical trials—Industry payments3SWOG Cancer Research NetworkClinical trials3Industry payments—Susan E. BatesClinical trials2Industry payments—Angiochem IncClinical trials1Industry payments—BeiGene USA, Inc.Clinical trials—Industry payments1Columbia UniversityClinical trials1Industry payments—Incyte CorporationClinical trials—Industry payments1National Institutes of Health Clinical Center (CC)Clinical trials1Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
0h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
14clinical trials

Investigator role on registered studies.

View trials ↓
4companies · 2022–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 28 Oct 2026

Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:

All 14 trial records: search, sort and filter.Explore →

Industry payments

Updated 28 Oct 2026

4 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:

All 5 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2020)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Blood & clotting

    100%
    Salt solutions72.5%
    Sodium Chloride100%
    Part D<11 patients
    Low Molecular Weight Heparin27.5%
    Enoxaparin Sodium100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Background & recognition

Updated 28 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • M.D.

    University of Arkansas for Medical Sciences

    1978
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗

Editorial & leadership roles

journal and society appointments
  • Editor-in-Chief

    The Oncologist

    2022
    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pmc.ncbi.nlm.nih.gov ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.